HK1115878A1 - (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors - Google Patents

(2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors

Info

Publication number
HK1115878A1
HK1115878A1 HK08111653.7A HK08111653A HK1115878A1 HK 1115878 A1 HK1115878 A1 HK 1115878A1 HK 08111653 A HK08111653 A HK 08111653A HK 1115878 A1 HK1115878 A1 HK 1115878A1
Authority
HK
Hong Kong
Prior art keywords
dioxoimidazolidin
acetamides
hydroxy
metalloproteinase inhibitors
metalloproteinase
Prior art date
Application number
HK08111653.7A
Other languages
English (en)
Inventor
Hans Wallberg
Ming Hua Xu
Guo Qiang Lin
Xin Sheng Lei
Piaoyang Sun
Kevin Parkes
Tony Johnson
Bertil Samuelsson
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of HK1115878A1 publication Critical patent/HK1115878A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK08111653.7A 2005-12-14 2008-10-23 (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors HK1115878A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05112144 2005-12-14
PCT/EP2006/012019 WO2007068474A1 (en) 2005-12-14 2006-12-13 (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors

Publications (1)

Publication Number Publication Date
HK1115878A1 true HK1115878A1 (en) 2008-12-12

Family

ID=35788378

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111653.7A HK1115878A1 (en) 2005-12-14 2008-10-23 (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors

Country Status (10)

Country Link
US (2) US8022092B2 (xx)
EP (1) EP1966153A1 (xx)
JP (1) JP5186384B2 (xx)
CN (1) CN101258132B (xx)
AU (1) AU2006326256B2 (xx)
BR (1) BRPI0619848A2 (xx)
CA (1) CA2628159A1 (xx)
HK (1) HK1115878A1 (xx)
TW (1) TWI361186B (xx)
WO (1) WO2007068474A1 (xx)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10875826B2 (en) 2006-09-07 2020-12-29 Emisphere Technologies, Inc. Process for the manufacture of SNAC (salcaprozate sodium)
EP2139850B1 (en) * 2007-04-09 2018-09-12 MethylGene Inc. Inhibitors of histone deacetylase
DK2597084T3 (en) 2010-07-08 2016-08-15 Kaken Pharma Co Ltd N-HYDROXYFORMAMIDE DERIVATIVE AND MEDICINAL CONTAINING SAME
EP2976331B1 (en) * 2013-03-21 2017-03-01 Sanofi-Aventis Deutschland GmbH Synthesis of hydantoin containing peptide products
WO2015107170A1 (en) * 2014-01-17 2015-07-23 Alphabeta Ab Novel ligands for prevention of neurotoxicity of the alzheimer's disease related amyloid-beta peptide
EP2907512A1 (en) 2014-02-14 2015-08-19 Commissariat A L'energie Atomique Et Aux Energies Alternatives Inhibitors of MMP-12 as antiviral Agents
CN106366168B (zh) * 2016-08-26 2020-09-15 上海交通大学 羊毛硫肽类抗菌肽及其脱氢衍生物的制备方法
CN112358414B (zh) * 2019-07-25 2022-03-22 中国科学院上海药物研究所 非天然氨基酸及其在蛋白质定点修饰和蛋白质相互作用中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6403632B1 (en) * 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6462063B1 (en) 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
AU2002230385A1 (en) 2000-09-25 2002-04-15 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
US6890915B2 (en) * 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)

Also Published As

Publication number Publication date
CN101258132A (zh) 2008-09-03
AU2006326256B2 (en) 2011-11-03
JP2009519281A (ja) 2009-05-14
JP5186384B2 (ja) 2013-04-17
CA2628159A1 (en) 2007-06-21
AU2006326256A1 (en) 2007-06-21
EP1966153A1 (en) 2008-09-10
CN101258132B (zh) 2012-04-25
TWI361186B (en) 2012-04-01
BRPI0619848A2 (pt) 2011-10-18
US8338471B2 (en) 2012-12-25
US20120015994A1 (en) 2012-01-19
US20090215846A1 (en) 2009-08-27
US8022092B2 (en) 2011-09-20
WO2007068474A1 (en) 2007-06-21
TW200825056A (en) 2008-06-16

Similar Documents

Publication Publication Date Title
TWI369351B (en) 2,4-diamino-pyrimidines as aurora inhibitors
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL192053A0 (en) 2-adamantylurea derivatives as selective 11??-hsd1 inhibitors
GB0500492D0 (en) Compound
GB0513702D0 (en) Compound
GB0506133D0 (en) Compound
EP1876179A4 (en) THIENOPYRIMIDONVERBINDUNGEN
GB0520955D0 (en) Compound
AP2281A (en) Novel compounds.
IL186130A0 (en) 3,4,5-substituted piperidines as renin inhibitors
IL186124A0 (en) 3,4,5-substituted piperidines as renin inhibitors
HU0500920D0 (en) New compounds
HU0500921D0 (en) New compounds
HK1115878A1 (en) (2,5-dioxoimidazolidin-i-yl)-n-hydroxy-acetamides as metalloproteinase inhibitors
ZA200805028B (en) Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
AP2337A (en) Motilide compounds.
GB0525323D0 (en) Compound
GB0509829D0 (en) Compound
GB0616173D0 (en) Compound
HU0500886D0 (en) New compounds
HU0500879D0 (en) New compounds
HU0500877D0 (en) New compounds
GB0516967D0 (en) Inhibitors
GB0524685D0 (en) Compound
GB0516378D0 (en) Compound

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20151213